Interleukin-10 (IL-10) and its receptor (IL-10R) have been foremost targets to understand
inflammatory bowel disease (IBD) pathogenesis. For the past several decades, IL-10-deficient (
Il10-/- ) mice were considered one of the best models to study immune-mediated
colitis. Several physiologic limitations with this model, e.g., delayed and varied disease onset, have hindered investigators in testing new clinical
therapies for IBD. In this article, we provide comprehensive guidance for using anti-IL-10R
monoclonal antibody (αIL-10R mAb) neutralization as a superior alternative model to study IBD. This article describes the feasibility of using αIL-10R mAb to induce chronic
colitis (within 4 weeks), perform time-dependent mechanistic studies, and assess the efficacy of IBD
therapeutics. This article also delineates protocols for in-house assays to critically assess
colitis and associated inflammatory parameters. Overall, we underscore αIL-10R mAb neutralization as a relevant immune-mediated murine
colitis model to study human
Crohn's disease. © 2021 Wiley Periodicals LLC. Basic Protocol 1: Induction of chronic
colitis in mice via αIL-10R mAb neutralization Basic Protocol 2: Biochemical evaluation of αIL-10R mAb neutralization-induced chronic
colitis Support Protocol 1: Stool analysis and scoring Support Protocol 2: Swiss roll method.